Overview

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2021-08-31

Target enrollment:

Participant gender:

Summary

A dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of venetoclax, in combination with gilteritinib, in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have relapsed or progressed after at least 1 prior therapy.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborators:

Astellas Pharma Inc
Genentech, Inc.

Treatments:

Venetoclax